Horm Metab Res 2010; 42(13): 967-976
DOI: 10.1055/s-0030-1267204
Humans, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

A Matter of the Heart: Myocardial Metastases in Neuroendocrine Tumors

H. Jann1 , T. Wertenbruch1 , U. Pape1 , C. Özcelik2 , T. Denecke3 , S. Mehl4 , B. Wiedenmann1 , M. Pavel1
  • 1Department of Hepatology and Gastroenterology, Charité, Berlin, Germany
  • 2Department of Cardiology, Charité, Berlin, Germany
  • 3Department of Radiology, Charité, Berlin, Germany
  • 4Department of Nuclear Medicine, Charité, Berlin, Germany
Further Information

Publication History

received 22.03.2010

accepted 09.09.2010

Publication Date:
22 October 2010 (online)

Abstract

The aim of the present study was to evaluate frequency, clinical spectrum, and treatment of myocardial metastases in patients with histologically proven neuroendocrine tumors by analysis of our database and literature review. The literature on cardiac metastases in patients with neuroendocrine tumors published from 1973 to the present was reviewed for age, sex, primary tumor localization, metastases, symptoms, complications, treatment, diagnostic methods, and histology. Patient records from our institution were analyzed retrospectively for cardiac metastases detected by any diagnostic means and detailed patient histories are given. 4 patients with myocardial metastases could be identified in our database (n=550) while literature review identified 41 published cases. Mean age at initial diagnosis was 57.5 years (females=13, males=28), primary tumor localizations were foregut (n=7), midgut (n=28), hindgut (n=1), or unknown (n=3). Carcinoid syndrome was reported for 28 patients. Cardiac involvement was right-ventricular only (n=10), left-ventricular only (n=11), or biventricular (n=10). Diagnosis was obtained by echocardiography (n=21), CT/MRI (n=12) and other methods (n=9), or by autopsy (n=9). We describe visualization of cardiac metastases by 68Ga-DOTATOC-PET/CT for the first time. Clinical presentation ranged from asymptomatic patients to cardiac arrest. Follow-up times ranged from <1 month up to 12 years. Clinicians treating patients with neuroendocrine tumors should be aware of the heart as a possible site of metastatic disease. Echocardiography and MRI are the methods of choice for follow-up, while PET/CT might contribute to earlier and more frequent detection. Management of cardiac metastases requires close cooperation between specialists of internal medicine, nuclear medicine, and cardiac surgery.

References

  • 1 Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours.  Lancet Oncol. 2008;  9 61-72
  • 2 Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.  Endocr Relat Cancer. 2008;  15 1083-1097
  • 3 Oberndorfer S. Karzinoide Tumoren des Dünndarms.  Frankf Z Pathol. 1907;  426-429
  • 4 Williams ED, Sandler M. Classification of Carcinoid Tumours.  Lancet. 1963;  1 238-239
  • 5 Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised Classification of Neuroendocrine Tumors of the Lung, Pancreas and Gut.  Virchows Arch. 1995;  425 547-560
  • 6 Heitz PU, Komminoth P, Perren A, Eng C. Tumours of the endocrine pancreas. In:, De Lellis RA, Lloyd RV, Heitz PU, editors WHO Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004: 177-182
  • 7 Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system.  Curr Opin Oncol. 2008;  20 1-12
  • 8 Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lorelius LE, Akerstrom G. Surgical-Treatment of Midgut Carcinoid-Tumors.  World J Surg. 1990;  14 377-385
  • 9 Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.  Endocr Relat Cancer. 2008;  15 409-427
  • 10 Hlatky R, Suki D, Sawaya R. Carcinoid metastasis to the brain.  Cancer. 2004;  101 2605-2613
  • 11 Patchell RA, Posner JB. Neurologic Complications of Carcinoid.  Neurology. 1986;  36 745-749
  • 12 Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK. Carcinoid Heart-Disease – Clinical and Echocardiographic Spectrum in 74 Patients.  Circulation. 1993;  87 1188-1196
  • 13 Pandya UH, Pellikka PA, Enriquez-Sarano M, Edwards WD, Schaff HV, Connolly HM. Metastatic carcinoid tumor to the heart: Echocardiographic-pathologic study of 11 patients.  J Am Coll Cardiol. 2002;  40 1328-1332
  • 14 Roberts MD. A Unique Heart Disease Associated With a Unique Cancer: Carcinoid Heart Disease.  Am J Cardiol. 1997;  80 251-256
  • 15 Maréchaux S, Dagorn J, Gaxotte V, Ennezat PV, Beregi JP, Bauters C, Deklunder G, le Tourneau T. Myocardial metastasis of a bronchial carcinoid.  Eur Heart J. 2007;  28 391
  • 16 Patel S, Heetun M, Gurjar SV, Szakacs S. A rare case of intra-cardiac metastasis from an appendiceal carcinoid tumour without liver metastases.  Int J Colorectal Dis. 2009;  24 993-994
  • 17 Patel CN, Anthoney A, Treanor D, Scarsbrook AF. Solitary Myocardial Metastasis From Small-Bowel Neuroendocrine Carcinoma.  J Clin Oncol. 2009;  27 1724-1726
  • 18 Howard RJ, Drobac M, Rider WD, Keane TJ, Finlayson J, Silver MD, Wigle ED, Rakowski H. Carcinoid heart disease: diagnosis by two-dimensional echocardiography.  Circulation. 1982;  66 1059-1065
  • 19 Baker BJ, Mcnee VD, Scovil JA, Bass KM, Watson JW, Bissett JK. Tricuspid Insufficiency in Carcinoid Heart-Disease – An Echocardiographic Description.  Am Heart J. 1981;  101 107-108
  • 20 Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EGE, Jager PL. Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results.  Crit Rev Oncol Hematol. 2009;  71 199-213
  • 21 Penz M, Kurtaran A, Vorbeck F, Oberhuber G, Raderer M. Case 2: Myocardial metastases from a carcinoid tumor.  J Clin Oncol. 2000;  18 1596-1597
  • 22 Yeung HWD, Imbriaco M, Zhang JJ, Macapinlac H, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide.  J Nucl Med. 1996;  37 1528-1530
  • 23 Strosberg J, Hoffe S, Hazelton T, Kvols L. External beam irradiation of myocardial carcinoid metastases: a case report.  J Med Case Reports. 2007;  1 95-98
  • 24 Mahmood S, De Llano SRM, Grewal RK. Focal myocardial uptake in a patient with carcinoid tumor by indium-111-pentetreotide on SPECT/CT.  Rev Esp Med Nucl. 2008;  27 355-357
  • 25 Fiebrich HB, Brouwers AH, Links TP, de Vries EGE. Myocardial metastases of carcinoid visualized by F-18-dihydroxy-phenyl-alanine positron emission tomography.  Circulation. 2008;  118 1602-1604
  • 26 Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R. PROMID Study Group . Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.  J Clin Oncol. 2009;  27 4656-4663
  • 27 Drake WM, Jenkins PJ, Phillips RR, Lowe DG, Grossman AB, Besser GM, Wass JAH. Intracardiac metastases from neuroendocrine tumours.  Clin Endocrinol. 1997;  46 517-522
  • 28 Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, Jensen R, Kos-Kudla B, Oberg K, O’Connor JM, Pavel ME, Vullierme MP. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin.  Neuroendocrinology. 2008;  87 40-46
  • 29 Schiller VL, Fishbein MC, Siegel RJ. Unusual Cardiac Involvement in Carcinoid-Syndrome.  Am Heart J. 1986;  112 1322-1323
  • 30 Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors.  J Clin Oncol. 1987;  5 1502-1522
  • 31 Fine SN, Gaynor ML, Isom OW, Dannenberg AJ. Carcinoid-Tumor Metastatic to the Heart.  Am J Med. 1990;  89 690-692
  • 32 Lund JT, Ehman RL, Julsrud PR, Sinak LJ, Tajik AJ. Cardiac Masses – Assessment by MR Imaging.  AJR Am J Roentgenol. 1989;  152 469-473
  • 33 Knott-Craig CJ, Schaff HV, Mullany CJ, Kvols LK, Moertel CG, Edwards WD, Danielson GK. Carcinoid Disease of the Heart – Surgical-Management of 10 Patients.  J Thorac Cardiovasc Surg. 1992;  104 475-481
  • 34 Davis G, Birbeck K, Roberts D, Naqvi N. Nonvalvular myocardial involvement in metastatic carcinoid disease.  Postgrad Med J. 1996;  72 751-752
  • 35 Hennington MH, Detterbeck FC, Szwerc MF, Fidler ME. Invasive carcinoid tumor of the heart.  J Surg Oncol. 1997;  66 264-266
  • 36 Schlegel PJ, Kralios AC, Terreros DA, Shami PJ. Malignant carcinoid tumor with myocardial metastases.  Am J Med. 1999;  107 643-645
  • 37 Kasi VS, Ahsanudin AN, Gilbert C, Orr L, Moran J, Sorrell VL. Isolated metastatic myocardial carcinoid tumor in a 48-year-old man.  Mayo Clin Proc. 2002;  77 591-594
  • 38 Shehata BM, Thomas JE, Doudenko-Rufforny I. Metastatic carcinoid to the conducting system - Is it a rare or merely unrecognized manifestation of carcinoid cardiopathy? A case report and review of the literature.  Arch Pathol Lab Med. 2002;  126 1538-1540
  • 39 Wee JO, Sepic JD, Mihaljevic T, Cohn LH. Metastatic carcinoid tumor of the heart.  Ann Thorac Surg. 2003;  76 1721-1722
  • 40 Goddard MJ, Atkinson C. Cardiac metastasis from a bronchial carcinoid: report of a case presenting with diffuse thickening of the left ventricular wall.  J Clin Pathol. 2004;  57 778-779
  • 41 Schiavone WA, Baker C, Prasad SK. Imaging myocardial carcinoid with T2-STIR CMR.  J Cardiovasc Magn Reson. 2008;  10 14-18

Correspondence

M. PavelMD 

University Medicine Berlin

Charité, Campus Virchow

Klinikum

Augustenburger Platz 1

13353 Berlin

Phone: +49/30/450 653 304

Fax: +49/30/450 553 902

Email: marianne.pavel@charite.de

    >